Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus docetaxel in adenocarcinoma NSCLC
NCT02231164Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in lung adenocarcinoma (LUAD) comparing Placebo + Docetaxel with Nintedanib + Docetaxel (2 arms). Primary endpoint: Disease Control Rate at 6 months. Started Oct 2014; status: terminated.
02
Drugs
nintedanib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT02231164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231164.